跳至主要内容
临床试验/ISRCTN10817487
ISRCTN10817487进行中(未招募)未知

World Hip Trauma Evaluation - LIT: Lidocaine Intravenous Trial

niversity of Oxford0 个研究点目标入组 416 人开始时间: 2022年1月19日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
416

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Platform inclusion criteria:
  • 1. Aged =60 years
  • 2. Diagnosed with a hip fracture that in the opinion of the treating surgeon may benefit from surgical treatment
  • No additional specific inclusion criteria for LIT.

排除标准

  • Platform exclusion criteria.
  • 1. Previous participation in the same randomised comparison
  • 2. A second hip fracture (other side) while the patient is still enrolled in the Platform following their first hip fracture
  • Additional specific exclusion criteria for LIT:
  • 1. Body weight estimated to be <40 kg or >100 kg
  • 2. Known subdural haematoma
  • 3. Known allergy to local anaesthetics
  • 4. Severely impaired renal (eGFR <30 ml.min-1) or hepatic (based on clinical history) function
  • 5. Patient has specific contraindications to lidocaine:
  • 5.1. All grades of atrioventricular block; severe myocardial depression; sino-atrial disorders
  • 5.2. Acute porphyria
  • 5. 3. Current congestive cardiac failure
  • 6. Concurrent participation in a clinical trial of a medicinal product or recent participation within 5 half-lives of the last dose of medicinal product
  • 7. Local anaesthetic nerve block administered within the previous 6 hours
  • 8. Known serum albumin <30 g/l

研究者

相似试验